Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Sales and Divestitures (2020 - 2022)

Historic Gains from Sales and Divestitures for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2022 value amounting to $46000.0.

  • Cullinan Therapeutics' Gains from Sales and Divestitures fell 8327.27% to $46000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $46000.0, marking a year-over-year decrease of 8327.27%. This contributed to the annual value of $46000.0 for FY2022, which is 8327.27% down from last year.
  • Cullinan Therapeutics' Gains from Sales and Divestitures amounted to $46000.0 in Q4 2022, which was down 8327.27% from $275000.0 recorded in Q4 2021.
  • In the past 5 years, Cullinan Therapeutics' Gains from Sales and Divestitures registered a high of $275000.0 during Q4 2021, and its lowest value of $46000.0 during Q4 2022.
  • Its 3-year average for Gains from Sales and Divestitures is $149786.0, with a median of $128358.0 in 2020.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 11424.45% in 2021, then plummeted by 8327.27% in 2022.
  • Cullinan Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $128358.0 in 2020, then soared by 114.24% to $275000.0 in 2021, then tumbled by 83.27% to $46000.0 in 2022.
  • Its Gains from Sales and Divestitures stands at $46000.0 for Q4 2022, versus $275000.0 for Q4 2021 and $128358.0 for Q4 2020.